Skip to main content

Gordon Reid is president & CEO of Goodreid Investment Counsel. His focus is on U.S. equities.

Top picks:

Apple Inc.
In an effort to create arguments to support the reasons for a drop in Apple's stock price, some have pointed to fundamental weakness in its operations – a mistake, in Goodreid's opinion. Apple's stock is in a momentum-led down draft that began with U.S. tax selling and has been exacerbated by general selling by shareholders who lack conviction. (Latest purchase: November, 2012 @ $508.)

Story continues below advertisement

United Therapeutics Corp.
A strong portfolio and active pipeline have led to excellent results for this biotech company. However investors are cautious, creating a compelling valuation which has significant upside potential while providing a floor to the stock price. (Latest purchase: December 2012 @ $50.)

Walgreen Co.
Recent events at Walgreen have led investors to be cautious but Goodreid believes that the resolution of the Express Scripts contract, the cost savings and synergies to be achieved with their acquisition of Boots in the U.K. and a strong management team will lead Walgreen's valuation back to its historical level of about 14 times earnings from the current 12 times. (Latest purchase: November 2012 @ $32.)

Past picks:

Google Inc.
Then: $618.07
Now: $720.76
Total return: +16.61 per cent

Oracle Corp.
Then: $29.87
Now: $34.25
Total return: +16.27 per cent

Apple Inc.
Then: $380.19
Now: $527.95
Total return: +40.12 per cent

Total return average: +24.33 per cent

Story continues below advertisement

Market outlook:

The U.S. equity market has quietly worked higher against a backdrop of negative and disconcerting macro developments, a very positive indicator. Interest rates and corporate profits are solidly bullish and if psychology improves to even a neutral position the equity market has significant upside.

Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies